TGRX-678

News alerts, weekly reports and conference planners

Company:

Shenzhen TargetRx

Drug class:

Bcr-abl tyrosine kinase inhibitor

Related drugs:

BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	TGRX-678 Sensitive: C3 – Early Trials TGRX-678 Sensitive : C3	TGRX-678 Sensitive: C3 – Early Trials TGRX-678 Sensitive : C3
BCR-ABL1 Y253H + BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 Y253H + BCR-ABL1 T315I	Chronic Myeloid Leukemia	ponatinib + TGRX-678 Sensitive: D – Preclinical ponatinib + TGRX-678 Sensitive : D	ponatinib + TGRX-678 Sensitive: D – Preclinical ponatinib + TGRX-678 Sensitive : D

Associations
(2)